Clinical Trials Logo

Clinical Trial Summary

The study consists in evaluating the analgesic efficacy of Gabapentin versus Placebo in the short term (72h) acute lumbosacral radiculalgia due to disc herniation. In addition to the usual analgesic treatment, the patient will receive gabapentin or placebo. During the three days of treatment, an evaluation of the pain and the tolerance will be performed within the two groups: experimental and control.


Clinical Trial Description

The objective of the study is to evaluate the analgesic efficacy of GABAPENTIN versus Placebo in 72h for hospitalised patients suffering from acute lumbosacral radiculalgia due to disc herniation. After signing the consent form, patient's clinical data will be collected and the patient will be allocated to one treatment arm by the randomisation process (ratio 1:1 and stratified on the strong opioid intake). Two treatment arms are possible : - Experimental group: GABAPENTINE per os - DAY1:300 mg - DAY 2: 600 mg - DAY3 : 900 mg - Control group: placebo (same dosage per day as GABAPENTINE). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04865042
Study type Interventional
Source Lille Catholic University
Contact Marie-Paule LEBITASY
Phone +33 3 20 22 52 69
Email urm@ghicl.net
Status Recruiting
Phase Phase 4
Start date February 2, 2022
Completion date February 2025